BACKGROUND:
A loss-of-function cardiac ryanodine receptor (RyR2) mutation, I4855M
+/–
, has recently been linked to a new cardiac disorder termed RyR2 Ca
2+
release deficiency syndrome (CRDS) as well as left ventricular noncompaction (LVNC). The mechanism by which RyR2 loss-of-function causes CRDS has been extensively studied, but the mechanism underlying RyR2 loss-of-function-associated LVNC is unknown. Here, we determined the impact of a CRDS-LVNC-associated RyR2-I4855M
+/–
loss-of-function mutation on cardiac structure and function.
METHODS:
We generated a mouse model expressing the CRDS-LVNC-associated RyR2-I4855M
+/–
mutation. Histological analysis, echocardiography, ECG recording, and intact heart Ca
2+
imaging were performed to characterize the structural and functional consequences of the RyR2-I4855M
+/–
mutation.
RESULTS:
As in humans, RyR2-I4855M
+/–
mice displayed LVNC characterized by cardiac hypertrabeculation and noncompaction. RyR2-I4855M
+/–
mice were highly susceptible to electrical stimulation–induced ventricular arrhythmias but protected from stress-induced ventricular arrhythmias. Unexpectedly, the RyR2-I4855M
+/–
mutation increased the peak Ca
2+
transient but did not alter the L-type Ca
2+
current, suggesting an increase in Ca
2+
-induced Ca
2+
release gain. The RyR2-I4855M
+/–
mutation abolished sarcoplasmic reticulum store overload–induced Ca
2+
release or Ca
2+
leak, elevated sarcoplasmic reticulum Ca
2+
load, prolonged Ca
2+
transient decay, and elevated end-diastolic Ca
2+
level upon rapid pacing. Immunoblotting revealed increased level of phosphorylated CaMKII (Ca
2+
-calmodulin dependent protein kinases II) but unchanged levels of CaMKII, calcineurin, and other Ca
2+
handling proteins in the RyR2-I4855M
+/–
mutant compared with wild type.
CONCLUSIONS:
The RyR2-I4855M
+/–
mutant mice represent the first RyR2-associated LVNC animal model that recapitulates the CRDS-LVNC overlapping phenotype in humans. The RyR2-I4855M
+/–
mutation increases the peak Ca
2+
transient by increasing the Ca
2+
-induced Ca
2+
release gain and the end-diastolic Ca
2+
level by prolonging Ca
2+
transient decay. Our data suggest that the increased peak-systolic and end-diastolic Ca
2+
levels may underlie RyR2-associated LVNC.